炎性因子与乳腺癌发病风险的前瞻性队列研究

The relationship between inflammatory factors and the risk of breast cancer in Kailuan cohort

目的在大型前瞻性队列研究基础上,探讨高敏C-反应蛋白(high sensitivity C-reactive protein,hsCRP)和中性粒细胞(neutrophil,NE)与女性乳腺癌发病风险的关联性。方法收集2006-2007年开滦研究队列女性人群体检数据和hsCRP及NE检测结果等基线信息。采用多因素Cox风险模型分析基线hsCRP水平及NE水平与女性乳腺癌发病风险比(HR)和95%可信区间(95%CI)。结果队列共纳入18 866例女性,末次随访至2015年12月31日,随访期间共收集新发乳腺癌183例。其中,hsCRP<1 mg/L组、1~3 mg/L组和>3 mg/L组新发乳腺癌9年累积发病率分别为829/10万、1 211/10万和1 495/10万,差异有统计学意义(χ~2=12.08,P=0.002)。Cox分析显示:hsCRP>3 mg/L组乳腺癌发病风险是hsCRP<1 mg/L组的1.71(95%CI:1.18~2.47,P=0.005)倍,差异有统计学意义。NE水平(<3.70×10~9/L和≥3.70×10~9/L)差异与乳腺癌发病风险无统计学意义(P>0.05)。结论基线hsCRP水平升高可能增加乳腺癌发病风险。

Objective To investigate whether elevated baseline levels of high sensitivity C-Reactive Protein(hsCRP)and neutrophil(NE)are associated with an increased risk of breast cancer in Kailuan female cohort.Methods Females from Kailuan cohort(2006-2007)were included in this study.Information on check-up,hsCRP and NE were collected at baseline for all subjects.Multivariable Cox proportional hazards regression models were used to calculate hazard ratios(HR)and 95%confidence intervals(95%CI)of association between baseline hsCRP and NE values and breast cancer risk.Results By December 31,2015,a total of 18 866 participants were enrolled in this study.During the follow-up,183 new cases of breast cancer were observed.All participants were divided into three groups according to the level of hsCRP(<1 mg/L,1-3 mg/L and>3 mg/L).The cumulative incidence of breast cancer were 829/10~5,1 211/10~5 and 1 495/10~5 in these 3 groups,respectively(χ~2=12.08,P=0.002).Compared with participants with lower hsCRP levels(<1 mg/L),individuals with the highest hsCRP(>3 mg/L)levels had significantly increased risk of breast cancer(HR=1.71,95%CI:1.18-2.47,P=0.005),howerver,we didn’t find the statistically significant association between NE level(<3.70×10~9/Lvs.≥3.70×10~9/L)and the risk of brease cancer(P>0.05).Conclusions Elevated levels of hsCRP at baseline might increase the risk of breast cancer in females.